MindBio Therapeutics Advances Toward Commercial Deployment of AI Solution for Impairment Detection in South America’s Mining Sector

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with a focus on industrial safety applications in South America’s mining sector. The company recently appointed Chilean policy specialist Felipe Leyton to lead commercialization efforts in the region, signaling a transition from technology development to field implementation in large enterprise environments.

Leyton brings extensive experience in national drug policy and workplace safety, having helped design and implement Chile’s ‘Zero Tolerance’ alcohol-impaired driving law as part of the country’s alcohol prevention framework. He also played a role in establishing Chile’s roadside drug testing program introduced in 2019. His appointment reflects MindBio’s strategy of aligning technical development with regulatory and industry expertise in markets where impairment detection is closely tied to workplace safety and compliance requirements.

MindBio is a biotechnology company commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for detection in various enterprise environments, including the mining industry, aviation, construction, and law enforcement.

For more details on the announcement, the full article is available at https://ibn.fm/JBNVq. The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF.